Nina Shah, MD, of the University of California, San Francisco School of Medicine, discussed the latest updates in multiple myeloma therapies and regimens in the frontline and subsequent settings presented at the 2019 ASH Annual Meeting. “After this meeting, we’re going to have a better idea of how to use the drugs we already have and generate some hypotheses about combining things and how to repurpose them later in different lines of therapy,” she said. ...
Advertisement
Peter M. Voorhees, MD, discussed B-cell maturation antigen (BCMA)-targeted CAR T-cell treatment strategies.
In this patient population, high-dose cytarabine consolidation is usually given in the inpatient setting.
The ongoing GO29781 study assessed mosunetuzumab in patients with relapsed/refractory B-cell NHL.
Amrita Krishnan, MD, discussed treatment options for patients with relapsed multiple myeloma.
CD123 expression is strongly correlated with disease-relevant cytogenetic and molecular alterations in AML.
Many patients report that they are not counseled about their concerns.
Advertisement
